MedPath

Cassava Sciences Announces Corporate Update on Alzheimer's Drug Simufilam

• Cassava Sciences will host a conference call and webcast on November 25th to provide a corporate update. • The update will likely cover the ongoing Phase 3 clinical trials of Simufilam for Alzheimer's disease. • Simufilam is an investigational oral small molecule drug targeting filamin A protein. • Cassava Sciences holds exclusive worldwide rights to Simufilam and related technologies.

Cassava Sciences Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company, announced it will hold a corporate update via conference call and webcast on Monday, November 25th, at 8:00 a.m. Eastern Time. The update is expected to provide insights into the progress of Simufilam, Cassava's investigational drug for Alzheimer's disease.
Simufilam is an oral, small molecule drug candidate currently in Phase 3 clinical trials as a potential treatment for Alzheimer's disease. The drug targets the filamin A protein, which is believed to play a role in the pathology of Alzheimer's. Cassava Sciences retains exclusive worldwide rights to Simufilam and its related technologies.
Cassava Sciences is focused on detecting and treating neurodegenerative diseases, with Alzheimer's disease as its primary focus. The corporate update is anticipated to cover key milestones and developments in the clinical trials of Simufilam. A replay of the audio webcast will be available on the company's website for 90 days following the live event.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cassava Sciences Announces Workforce Reduction and Provides Update on Alzheimer's Program

Cassava Sciences is reducing its workforce by approximately 33% as part of cost-saving measures following Phase 3 trial results.
Topline data from the REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's is expected in late Q1 or early Q2 2025.

Cassava Sciences' Simufilam Fails in Phase 3 Alzheimer's Trial, Program Halted

Cassava Sciences' Phase 3 trial of simufilam in mild-to-moderate Alzheimer's disease did not meet its co-primary endpoints, assessing cognition and function at 52 weeks.
The company has decided to discontinue its second Phase 3 trial, ReFocus-ALZ, and the Open Label Extension study following the disappointing results.

Cassava Sciences' Simufilam Fails Phase 3 Alzheimer's Trial, Halting Further Development

Cassava Sciences' Phase 3 ReThink-ALZ trial of simufilam in mild-to-moderate Alzheimer's disease did not meet its co-primary endpoints, indicating no significant cognitive or functional benefit.
Due to the disappointing results, Cassava Sciences is discontinuing its second Phase 3 trial, ReFocus-ALZ, and the Open Label Extension study, effectively halting simufilam's development.

Cassava Sciences to Provide Corporate Update on Alzheimer's Drug Simufilam

Cassava Sciences will host a conference call and webcast on November 25th to provide a corporate update.
The update will likely cover the ongoing Phase 3 clinical trials of Simufilam, an investigational drug for Alzheimer's disease.

Cassava Sciences Announces Corporate Update on Alzheimer's Drug Simufilam

Cassava Sciences will hold a conference call and webcast on November 25th to provide a corporate update.
The update will likely cover the ongoing Phase 3 clinical trials of Simufilam for Alzheimer's disease.

Cassava Sciences Bolsters Commercial Strategy with Freda Nassif as Chief Commercial Officer

Cassava Sciences appointed Freda Nassif as Chief Commercial Officer to spearhead commercial strategies for simufilam, their Alzheimer's drug candidate.
Ms. Nassif brings 25 years of experience in developing commercial strategies for FDA-approved drugs from companies like Pfizer and Novartis.

Cassava Sciences Nears Completion of Simufilam Phase 3 Alzheimer's Trial

Cassava Sciences anticipates releasing top-line data from its RETHINK-ALZ trial of simufilam for Alzheimer's disease by the end of 2024.
The RETHINK-ALZ study has completed enrollment with approximately 800 patients, while the REFOCUS-ALZ study has about 1,100 patients enrolled.

Cassava Sciences' Simufilam Nears Phase 3 Readout Amidst Data Integrity Concerns

Cassava Sciences is nearing the release of Phase 3 trial results for simufilam, its investigational Alzheimer's disease treatment, marking a crucial step for the company.
The company faces scrutiny following SEC charges against former executives and a consultant for allegedly manipulating Phase 2 clinical trial data.

Kazia Therapeutics to Meet with FDA on Paxalisib's Glioblastoma Registration Pathway

Kazia Therapeutics will meet with the FDA in December 2024 to discuss potential registration pathways for paxalisib in newly diagnosed glioblastoma (GBM).
The discussion follows Phase II/III GBM-AGILE trial results showing clinically meaningful overall survival improvement in newly diagnosed, unmethylated GBM patients treated with paxalisib.

Cassava Sciences' Simufilam Maintains Safety Profile in Phase 3 Alzheimer's Trials

An independent Data and Safety Monitoring Board (DSMB) has endorsed the continuation of Cassava Sciences' Phase 3 trials for simufilam in Alzheimer's disease.
The DSMB's recommendation is based on an interim safety review, with no modifications suggested for the ongoing clinical trials.

Reference News

[1]
Cassava Sciences to Hold Corporate Update on November 25th - GlobeNewswire
globenewswire.com · Nov 25, 2024

Cassava Sciences, Inc. (NASDAQ: SAVA) will hold a conference call and webcast on Nov. 25th at 8:00 a.m. ET. Simufilam, a...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy